TCGA-S5-A6DX-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 1.839684625
- os_event
- true
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A5YL-01A-12R-A29R-07 | — | B | 0.893 |
| 2 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.872 |
| 3 | SRR1411024 | GTEX | — | 0.838 |
| 4 | TCGA-OL-A66N-01A-12R-A31O-07 | — | B | 0.832 |
| 5 | TCGA-KQ-A41P-01A-12R-A33J-07 | — | — | 0.823 |
| 6 | TCGA-XF-A8HF-01A-11R-A36F-07 | — | — | 0.812 |
| 7 | dc3154b7-6ae4-446a-8a80-91a86c57cefe | — | — | 0.804 |
| 8 | SRR5088872 | — | — | 0.802 |
| 9 | MNG431 | — | — | 0.797 |
| 10 | R57 | — | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |